Coya Therapeutics, Inc. (NASDAQ:COYA) Insider Acquires $19,972.70 in Stock

Coya Therapeutics, Inc. (NASDAQ:COYA) insider Fred Grossman purchased 2,710 shares of the stock in a transaction dated Monday, November 11th. The shares were bought at an average price of $7.37 per share, with a total value of $19,972.70. Following the completion of the acquisition, the insider now directly owns 2,710 shares of the company’s stock, valued at approximately $19,972.70. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Coya Therapeutics Stock Performance

COYA opened at $6.81 on Friday. The company’s fifty day moving average price is $7.11 and its two-hundred day moving average price is $7.01. Coya Therapeutics, Inc. has a 1-year low of $4.75 and a 1-year high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.15. Equities analysts forecast that Coya Therapeutics, Inc. will post -1.15 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Chardan Capital reiterated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Monday.

Hedge Funds Weigh In On Coya Therapeutics

Hedge funds have recently modified their holdings of the company. Gilbert & Cook Inc. bought a new stake in shares of Coya Therapeutics during the 2nd quarter worth $61,000. Renaissance Technologies LLC purchased a new position in Coya Therapeutics during the 2nd quarter valued at about $101,000. GHP Investment Advisors Inc. purchased a new stake in shares of Coya Therapeutics in the third quarter worth $169,000. Finally, Vanguard Group Inc. grew its stake in Coya Therapeutics by 772.3% in the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after buying an additional 750,338 shares in the last quarter. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.